Healthcare -
Biotechnology - NASDAQ - US
$ 4.265
0.353 %
$ 329 M
Market Cap
-4.14
P/E
1. INTRINSIC VALUE
Balance Sheet
Corvus Pharmaceuticals, Inc.
| Current Assets | 54.4 M |
| Cash & Short-Term Investments | 52 M |
| Receivables | 216 K |
| Other Current Assets | 2.23 M |
| Non-Current Assets | 14.5 M |
| Long-Term Investments | 12.5 M |
| PP&E | 1.33 M |
| Other Non-Current Assets | 632 K |
| Current Liabilities | 35.4 M |
| Accounts Payable | 2.58 M |
| Short-Term Debt | 185 K |
| Other Current Liabilities | 32.6 M |
| Non-Current Liabilities | 937 K |
| Long-Term Debt | 1.87 M |
| Other Non-Current Liabilities | -937 K |
EFFICIENCY
Earnings Waterfall
Corvus Pharmaceuticals, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 27.5 M |
| Operating Income | -27.5 M |
| Other Expenses | 34.7 M |
| Net Income | -62.3 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Corvus Pharmaceuticals, Inc.
| Net Income | -62.3 M |
| Depreciation & Amortization | 85 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 3 M |
| Change in Working Capital | 0 |
| Others | 35.4 M |
| Free Cash Flow | -25.4 M |
Wall Street Analysts Price Targets
Corvus Pharmaceuticals, Inc.
Wall Street analysts predict an average 1-year price target for CRVS of $12 , with forecasts ranging from
a
low of
$11 to a high of $13 .
CRVS Lowest Price Target
Wall Street Target
11 USD
157.91%
CRVS Average Price Target
Wall Street Target
12 USD
181.36%
CRVS Highest Price Target
Wall Street Target
13 USD
204.81%
4. DIVIDEND
ANALYSIS
CRVS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Corvus Pharmaceuticals, Inc.
Sold
0-3 MONTHS
9.78 M USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
3 Penny Stocks Wall Street Sees With 243% Upside
“The Next NVIDIA” Could Change Your Life NVIDIA has returned 250-fold in the past 10 years as artificial intelligence took off.
247wallst.com
- 1 month ago
Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2 All three cohorts show separation from placebo with statistically significant difference from placebo at day 28 Cohort 3 demonstrates clinically meaningful reduction in itch as early as day 8 Enrollment initiated in extension cohort study exploring the same cohort 3 dose (200 mg BID) for a longer 8-week treatment period SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis.
globenewswire.com
- 1 month ago
Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at the 2025 Jefferies Global Healthcare Conference, which is being held in New York, NY. The presentation will be on Thursday, June 5 from 9:20-9:50 am ET.
globenewswire.com
- 1 month ago
Why Is Corvus Pharmaceuticals Stock Soaring On Friday?
Corvus Pharmaceuticals, Inc. CRVS on Thursday released new interim data from the Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis.
benzinga.com
- 2 months ago
Corvus Pharmaceuticals, Inc. (CRVS) Q1 2025 Earnings Call Transcript
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, Investor Relations Leiv Lea - Chief Financial Officer Richard Miller - Chief Executive Officer Conference Call Participants Aydin Huseynov - Ladenburg Graig Suvannavejh - Mizuho Securities Li Watsek - Cantor Jeff Jones - Oppenheimer Roger Song - Jefferies Sean Lee - H.C. Wainwright Operator Good afternoon, everyone.
seekingalpha.com
- 2 months ago
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results
Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2
globenewswire.com
- 2 months ago
Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Data continue to demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2
globenewswire.com
- 2 months ago
Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025
Data from Cohorts 1-3 of trial to be presented in an oral session and poster at the Society for Investigative Dermatology (SID) 2025 Annual Meeting
globenewswire.com
- 3 months ago
Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors
SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that Richard van den Broek, managing partner at HSMR Advisors, has been appointed to the Company's board of directors. Mr. van den Broek has more than 30 years of experience in the life sciences industry as an investor, biotechnology equity research analyst and board member.
globenewswire.com
- 3 months ago
Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials
Corvus Pharmaceuticals' leading drug candidate is Soquelitinib, which has broad potential across PTCL, atopic dermatitis, and ALPS. Unfortunately, it seems Corvus' early AD data might have disappointed investors (at least initially). Still, Soquelitinib's promising Phase 3 PTCL trial results are due late 2026. Its PFS metrics might help it to differentiate from other standard chemotherapy treatments.
seekingalpha.com
- 3 months ago
Corvus Pharmaceuticals: Now At Cruising Altitude
Corvus Pharmaceuticals' stock has experienced volatility due to mixed clinical data, particularly from their lead asset soquelitinib's Phase 1 trial in atopic dermatitis. The company has promising developments, including a Phase 2 trial for autoimmune lymphoproliferative syndrome and potential solid tumor trials, but current data is inconclusive. Significant shareholder activity, including warrant exercises, has impacted stock price and ownership dynamics, with potential future dilution if more shares are issued.
seekingalpha.com
- 3 months ago
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call Transcript
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q4 2024 Earnings Conference Call March 25, 2025 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, IR Leiv Lea - CFO Richard Miller - CEO Conference Call Participants Jeff Jones - Oppenheimer Aydin Huseynov - Ladenburg Thalmann Cha Cha Yang - Jefferies Daniel Bronder - Cantor Sean Lee - H.C. Wainwright Operator Good afternoon, everyone.
seekingalpha.com
- 3 months ago
8. Profile
Summary
Corvus Pharmaceuticals, Inc. CRVS
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 329 M
Dividend Yield
0.00%
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
Contact
863 Mitten Road, South San Francisco, CA, 94010
https://www.corvuspharma.com
IPO
Date
March 23, 2016
Employees
31
Officers
Dr. Peter A. Thompson FACP, M.D.
Co-Founder & Independent Director
Mr. Jeffrey S. Arcara
Senior Vice President & Chief Business Officer
Mr. Leiv Lea
Chief Financial Officer
Dr. Richard A. Miller M.D.
Co-Founder, President, Chief Executive Officer & Chairman of the Board
Dr. William Benton Jones Ph.D.
Senior Vice President of Pharmaceutical Development